This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Meridian Bioscience Past Earnings Performance

Past criteria checks 1/6

Key information

25.3%

Earnings growth rate

24.7%

EPS growth rate

Medical Equipment Industry Growth	4.3%
Revenue growth rate	13.0%
Return on equity	11.5%
Net Margin	12.7%
Last Earnings Update	30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Meridian Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:MR4 Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 22	333	42	88	24
30 Jun 22	344	43	90	24
31 Mar 22	339	62	86	24
31 Dec 21	313	60	80	24
30 Sep 21	318	71	76	24
30 Jun 21	306	71	76	25
31 Mar 21	327	87	76	25
31 Dec 20	299	70	74	25
30 Sep 20	254	46	71	24
30 Jun 20	240	44	68	22
31 Mar 20	204	21	64	20
31 Dec 19	197	19	61	19
30 Sep 19	201	24	62	18
30 Jun 19	203	26	62	16
31 Mar 19	207	27	64	16
31 Dec 18	213	26	68	16
30 Sep 18	214	24	70	17
30 Jun 18	210	24	69	18
31 Mar 18	209	18	68	17
31 Dec 17	206	22	66	17
30 Sep 17	201	22	63	16
30 Jun 17	198	21	63	15
31 Mar 17	199	30	63	15
31 Dec 16	195	30	61	14
30 Sep 16	196	32	59	14
30 Jun 16	195	35	58	13
31 Mar 16	192	36	55	13

Quality Earnings: MR4 has a large one-off loss of $21.2M impacting its September 30 2022 financial results.

Growing Profit Margin: MR4's current net profit margins (12.7%) are lower than last year (22.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MR4's earnings have grown significantly by 25.3% per year over the past 5 years.

Accelerating Growth: MR4's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MR4 had negative earnings growth (-40.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (-37.2%).

This company listing is no longer active

Meridian Bioscience Past Earnings Performance

Past criteria checks 1/6

Key information

Recent past performance updates

Full year 2022 earnings released: EPS: US$0.97 (vs US$1.65 in FY 2021)

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 profit in 3Q 2021)

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

Recent updates

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Full year 2022 earnings released: EPS: US$0.97 (vs US$1.65 in FY 2021)

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 profit in 3Q 2021)

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Insufficient new directors

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022

Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience, Inc. Announces Board Changes

Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Insufficient new directors

Insufficient new directors

Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021

Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix

Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020)

Meridian Bioscience, Inc. Announces the Launch of the Lyo-Ready DNA LAMP Mix

Investor sentiment improved over the past week

President recently sold €210k worth of stock

Investor sentiment improved over the past week

Meridian Bioscience, Inc. Announces the Launch of New Air-Dryable Direct DNA qPCR Blood Mix

Meridian Bioscience Provides A Further Update on the Revogene® Sars-Cov-2 Eua Submission

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides an Update on the Revogene SARS-CoV-2 EUA Submission

First quarter 2021 earnings released: EPS US$0.62 (vs US$0.066 in 1Q 2020)

Revenue beats expectations

Meridian Bioscience, Inc. Raises Consolidated Earnings Guidance for the Fiscal Year 2021

Investor sentiment improved over the past week

Meridian’s Air-Dryable Master Mixes Replace Lyophilization in the Manufacturing of Molecular Assays

New 90-day high: €18.70

Meridian Bioscience, Inc. to Report Q1, 2021 Results on Feb 05, 2021

Investor sentiment improved over the past week

New 90-day high: €17.70

New 90-day high: €17.00

Meridian Bioscience, Inc., Annual General Meeting, Jan 27, 2021

Meridian Bioscience, Inc. Launches Its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers

Independent Director recently bought €74k worth of stock

Market bids up stock over the past week

Full year 2020 earnings released: EPS US$1.08

Revenue beats expectations

Market pulls back on stock over the past week

Meridian Bioscience, Inc. Launches Complete Solution Improving the Development of Cancer Diagnostic Tests

New 90-day low - €11.90

Third quarter earnings released

New 90-day high - €22.20

Meridian Bioscience, Inc. (NasdaqGS:VIVO) completed the acquisition of Exalenz Bioscience Ltd (TASE:EXEN) from Mori Arkin and others.

Meridian Bioscience, Inc. to Report Q3, 2020 Results on Aug 07, 2020

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Revenue & Expenses Breakdown
Beta